Donald Klein

Summary

Publications

  1. ncbi request reprint Harmful dysfunction, disorder, disease, illness, and evolution
    D F Klein
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    J Abnorm Psychol 108:421-9. 1999
  2. ncbi request reprint Flawed meta-analyses comparing psychotherapy with pharmacotherapy
    D F Klein
    Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 157:1204-11. 2000
  3. ncbi request reprint Comments on psychiatric education
    Donald F Klein
    New York State Psychiatric Institute, New York, New York, USA
    Acad Psychiatry 29:128-33. 2005
  4. ncbi request reprint The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children
    Donald F Klein
    New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:689-99. 2006
  5. doi request reprint The loss of serendipity in psychopharmacology
    Donald F Klein
    Phyllis Green and Randolph Cowen Institute for Pediatric Neuroscience, NYU Child Study Center, New York, New York 10016, USA
    JAMA 299:1063-5. 2008
  6. ncbi request reprint FDA post-marketing safety decisions
    Donald F Klein
    New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    J Clin Psychiatry 67:1305-6. 2006
  7. ncbi request reprint Commentary by a clinical scientist in psychopharmacological research
    Donald F Klein
    Psychiatry, Emeritus, Columbia University, New York, USA
    J Child Adolesc Psychopharmacol 17:284-7. 2007
  8. ncbi request reprint When should a trial of fluoxetine for major depression be declared failed?
    Frederic M Quitkin
    Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 160:734-40. 2003
  9. ncbi request reprint Fostering treatment advances
    Donald F Klein
    J Clin Psychopharmacol 22:541-2. 2002
  10. ncbi request reprint Improving the pedagogy associated with the teaching of psychopharmacology
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 31:211-7. 2007

Research Grants

Detail Information

Publications22

  1. ncbi request reprint Harmful dysfunction, disorder, disease, illness, and evolution
    D F Klein
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    J Abnorm Psychol 108:421-9. 1999
    ..This analysis refutes the implication that deviance and illness are equivalent. The resolution of this debate is practically relevant to emphasizing areas of research investment, such as therapeutics...
  2. ncbi request reprint Flawed meta-analyses comparing psychotherapy with pharmacotherapy
    D F Klein
    Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 157:1204-11. 2000
    ..The author sought to illustrate the invalidity of meta-analyses that claim to quantitatively compare the benefits of psychotherapy to pharmacotherapy in patients with psychiatric disorders...
  3. ncbi request reprint Comments on psychiatric education
    Donald F Klein
    New York State Psychiatric Institute, New York, New York, USA
    Acad Psychiatry 29:128-33. 2005
  4. ncbi request reprint The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children
    Donald F Klein
    New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:689-99. 2006
    ..Proper prospective post-marketing surveillance by linked computerized medical records is a crucial issue that deserves major public and political attention and prompt action...
  5. doi request reprint The loss of serendipity in psychopharmacology
    Donald F Klein
    Phyllis Green and Randolph Cowen Institute for Pediatric Neuroscience, NYU Child Study Center, New York, New York 10016, USA
    JAMA 299:1063-5. 2008
  6. ncbi request reprint FDA post-marketing safety decisions
    Donald F Klein
    New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    J Clin Psychiatry 67:1305-6. 2006
  7. ncbi request reprint Commentary by a clinical scientist in psychopharmacological research
    Donald F Klein
    Psychiatry, Emeritus, Columbia University, New York, USA
    J Child Adolesc Psychopharmacol 17:284-7. 2007
  8. ncbi request reprint When should a trial of fluoxetine for major depression be declared failed?
    Frederic M Quitkin
    Department of Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Psychiatry 160:734-40. 2003
    ..The authors sought to determine how many weeks a fluoxetine trial with no improvement should continue before treatment is changed...
  9. ncbi request reprint Fostering treatment advances
    Donald F Klein
    J Clin Psychopharmacol 22:541-2. 2002
  10. ncbi request reprint Improving the pedagogy associated with the teaching of psychopharmacology
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 31:211-7. 2007
    ..The focus was on whether "improving the teaching-learning process" in psychiatric residency programs could improve clinical practice...
  11. ncbi request reprint Improving detection of adverse effects of marketed drugs
    Donald F Klein
    University of Pennsylvania, Philadelphia, PA 19104 6178, USA
    JAMA 298:333-4. 2007
  12. ncbi request reprint Peer review and data access
    Donald F Klein
    New York State Psychiatric Institute, Columbia University, New York 10032, USA
    Cortex 38:412. 2002
  13. ncbi request reprint Improving clinical trials: American Society of Clinical Psychopharmacology recommendations
    Donald F Klein
    New York State Psychiatric Institute and Columbia University, Unit 22, 1051 Riverside Dr, New York, NY 10032, USA
    Arch Gen Psychiatry 59:272-8. 2002
    ..The scope of inquiry included identifying means of shifting institutional and regulatory assumptions and processes, even to the point of seeking appropriate national incentives...
  14. ncbi request reprint Accurate meta-analytical assessment of "true antidepressant effects" needed
    Frederic M Quitkin
    J Clin Psychiatry 66:1192; author reply 1192-3. 2005
  15. ncbi request reprint Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients
    Frederic M Quitkin
    Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA
    J Clin Psychiatry 66:670-6. 2005
    ..This effectiveness study assessed remission rates in patients who had the opportunity to receive up to 3 antidepressant trials if unresponsive...
  16. ncbi request reprint Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions
    Jonathan W Stewart
    New York State Psychiatric Institute, United States Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
    J Affect Disord 86:161-7. 2005
    ....
  17. ncbi request reprint SSRIs in children and suicide
    Donald F Klein
    Science 305:1401. 2004
  18. ncbi request reprint Genes and environment: nosology and psychiatry
    Donald F Klein
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY 10032, USA
    Neurotox Res 6:11-5. 2004
    ..However, a syndrome has no claim for etiological homogeneity. Therefore, linkage studies are plagued by phenocopies that amount to false positives. An attempt to deal with the phenocopy problem in the area of depression is presented...
  19. ncbi request reprint A reappraisal of atypical depression
    Frederic M Quitkin
    Am J Psychiatry 160:798-800; author reply 800-1. 2003
  20. ncbi request reprint Are there differences between women's and men's antidepressant responses?
    Frederic M Quitkin
    Department of Therapeutics, New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, New York 10032, USA
    Am J Psychiatry 159:1848-54. 2002
    ..The study examined a large data set to determine whether patients' sex affected the outcome of antidepressant treatment...
  21. ncbi request reprint A typological model for estimation of drug and placebo effects in depression
    Donald C Ross
    New York State Psychiatric Institute, New York, New York 10032, USA
    J Clin Psychopharmacol 22:414-8. 2002
    ....
  22. doi request reprint An open-label pilot study to evaluate the efficacy of sildenafil citrate in middle-aged men with late-onset dysthymia
    Guy Orr
    Department of Psychiatry Sheba Medical Center, Tel Hashomer, Israel
    J Nerv Ment Dis 196:496-500. 2008
    ..Sildenafil citrate might have an antidepressant effect on late onset DD, that is not attributable to improvement in erectile function. Possible explanations for this effect are offered. Larger placebo controlled studies are warranted...

Research Grants2

  1. Psychobiology of IV Naloxone & Lactate in Normals
    Donald Klein; Fiscal Year: 2005
    ..This would further validate this model. It may also suggest new approaches to anti-panic agents, such as mixed opiate agonist-antagonist. ..